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Abstract
In patients with community-onset acute pyelonephritis (CO-APN), assessing the risk factors for poor clinical response after 72 h of
antibiotic treatment (early clinical failure) is important. The objectives of this study were to deﬁne those risk factors, and to assess whether
early clinical failure inﬂuences mortality and treatment outcomes. We prospectively collected the clinical and microbiological data of women
with CO-APN in South Korea from March 2010 to February 2012. The numbers of cases in the early clinical success and early clinical failure
groups were 840 (79.1%) and 222 (20.9%), respectively. Final clinical failure and mortality were higher in the early clinical failure group than
in the early clinical success group (14.9% vs 2.3%, p <0.001; 6.8% vs 0.1%, p 0.001, respectively). In a multiple logistic regression model, the
risk factors for early clinical failure among the total 1062 patients were diabetes mellitus (OR 1.5; 95% CI 1.1–2.1), chronic liver diseases
(OR 3.3; 95% CI 1.6–6.7), malignancy (OR 2.2; 95% CI 1.1–4.4), Pitt score ≥2 (OR 2.5; 95% CI 1.6–3.8), presence of azotaemia (OR 1.8; 95%
CI 1.2–2.7), white blood cell count ≥20 000/mm3 (OR 2.5; 95% CI 1.6–4.0), serum C-reactive protein level ≥20 mg/dL (OR 1.7; 95% CI 1.2–
2.4), and history of antibiotic usage within the previous year (OR 1.5; 95% CI 1.1–2.2). Analysing the subgroup of 743 patients with CO-APN
due to Enterobacteriaceae, ﬂuoroquinolone resistance of the uropathogen was another factor associated with early clinical failure (OR 1.7;
95% CI 1.1–2.5). Simple variables of underlying diseases, previous antibiotic usage and initial laboratory test outcomes can be used to decide
on the direction of treatment in CO-APN.
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Introduction
Acute pyelonephritis (APN) is an upper urinary tract infection
characterized by inﬂammation of the renal parenchyma and
renal pelvis typically due to a bacterial infection ascending from
the bladder. It is a common bacterial infection in the
community, especially in otherwise healthy women. It has
been estimated that women are almost ﬁve times as likely as
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men to be hospitalized for APN (11.7/10 000 vs 2.4/10 000)
[1,2]. In South Korea, the annual incidence of APN is 35.7 per
10 000 people, with the rate of hospitalization for APN being
9.96 per 10 000 women and 1.18 per 10 000 men [3]. Several
factors such as frequency of sexual intercourse in the previous
30 days, diabetes mellitus, urinary incontinence and a family
history of urinary tract infections have been shown to increase
the risk of APN [4,5].
Although APN is a common disease and is usually treated
successfully with antimicrobial agents, it often requires hospi-
talization, and when accompanied by bacteraemia has a
mortality rate of 5–20% [6–8]. In a retrospective study,
factors associated with death among men and women with
APN included age >65 years, septic shock and bedridden
status; immunosuppression was a risk factor for death among
men only and recent antibiotic use was a risk factor among
women only [9]. Another study analysing uncomplicated APN
in women showed that hospitalization at baseline, the pres-
ence of a resistant infecting organism, diabetes mellitus and a
history of kidney stones were signiﬁcant risk factors for a poor
clinical response [10]. Patients with APN who have a risk of
death or of a poor clinical response need hospitalization and
close observation.
In clinical practice, if patients with APN do not show a
clinical response after 72 h of antibiotic treatment (early
clinical failure), radiological imaging of the urinary tract,
investigation of other complicating factors or modiﬁcation of
the initial antimicrobial regimen in line with antibiotic
susceptibility results are usually required [11]. Objective
assessment of the risk factors for a poor clinical response
after 72 h of treatment would help physicians to determine
at the initial presentation whether hospitalization is needed.
Furthermore, the increase of antimicrobial resistance among
urinary pathogens in community-onset APN (CO-APN)
makes the assessment of antibiotic resistance even more
necessary [11]. We anticipate that demographic and clinical
factors such as age, menopausal status, diabetes mellitus or
other underlying diseases, simple laboratory test results that
can be obtained in a short time in most hospitals and risk
factors for antimicrobial resistance could be used to
predict which APN patients are likely to suffer early clinical
failure.
The objectives of our study were to deﬁne and charac-
terize the risk factors for early clinical failure in CO-APN
patients, and to establish whether early clinical failure has an
effect on mortality and ﬁnal treatment outcomes. To this
end, we prospectively collected and analysed the clinical and
microbiological data of women with CO-APN who visited
11 hospitals in South Korea from March 2010 to February
2012.
Materials and Methods
Study design
This study was a prospective, observational, multicentre
cohort study of women with CO-APN in South Korea
performed from 1 March 2010 to 28 February 2012. The
study was conducted in 11 South Korean university hospitals
with between 582 and ~1250 beds each. The hospitals that
participated in this study were located throughout the Korean
peninsula (three in Seoul, three in Gyeonggi-do, two in
Incheon, two in Daegu and one in Busan), and ten were
academic hospitals. The study protocol was approved by the
institutional review boards of each participating centre. The
institutional review boards waived the requirement for written
informed consent from patients. All the data collected for this
study were kept conﬁdential.
Patient population
All patients admitted to the participating hospitals for
CO-APN from March 2010 to February 2012 were enrolled
consecutively in the study. APN was deﬁned as fever ≥37.8°C,
and presence of at least three of the followings: (i) pain in the
ﬂanks; (ii) costovertebral angle tenderness on examination; (iii)
symptoms of lower urinary tract infection (dysuria, urgency,
frequency, pain in the suprapubic region); (iv) pyuria (≥5–9
leucocytes/high-power ﬁeld); and (v) leucocytosis (peripheral
white blood cell (WBC) count >11 600/mm3 or polymorpho-
nuclear cells plus bands >65%) [12,13]. CO-APN was deﬁned
as a case presenting to the emergency department or an
outpatient clinic from the community with the signs of APN
just described. Any patient who was diagnosed with APN
>48 h after admission or with a urinary-catheter-related
infection was excluded from the study. Patients under
15 years, of male gender, those with other reasons for pyuria
and fever and those with insufﬁcient data were also excluded.
Cases of CO-APN were enrolled at admission by an infectious
diseases specialist.
Data collection and deﬁnitions
The clinical characteristics of all the eligible patients were
collected prospectively using a web-based medical records
system. Variables included demographic features (age, meno-
pause status), clinical features and treatment outcomes.
Treatment outcome was assessed in terms of early clinical
response after 72 h of treatment, ﬁnal clinical outcome
(clinical cure or failure), microbiological outcome (microbio-
logical eradication or failure), hospitalization days, and febrile
days. Early clinical success was deﬁned if the following criteria
were met at 72 h after the start of empirical antimicrobial
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therapy: (i) resolution of fever and (ii) improvement of urinary
tract symptoms or signs. Those patients who did not meet the
criteria of early clinical success were regarded as early clinical
failures. Clinical cure was deﬁned as resolution of fever and
absence of urinary tract symptoms or signs upon the
completion of therapy and/or within 7–14 days of follow up
after completion of therapy. Clinical failure was deﬁned as
recurrence of urinary tract symptoms and/or signs within 7–
14 days of follow up after completion of therapy, or death.
Microbiological failure was deﬁned as detection of the same
pathogen or different pathogens in urine culture within 7–
14 days of follow up after completion of therapy. Patients who
did not have follow-up cultures were excluded from the
analysis of microbiological outcome.
Risk factor variables included age, history of antibiotic usage
within the previous year, history of urinary tract infection,
hospital admission history within the previous year, meno-
pause status, diabetes mellitus, underlying co-morbidities and
structural or functional abnormalities of the urinary tract [14–
17]. The underlying systemic co-morbidities were: cerebro-
vascular accident, congestive heart failure, malignancy, chronic
liver disease, renal disease, dementia, etc. Co-morbidities of
the urinary tract were: neurogenic bladder, urolithiasis,
history of urinary tract catheterization for 1 month, etc. Pitt
score was measured as a risk factor variable: (i) oral
temperature: 2 points for a temperature of ≤35°C or
≥40°C, 1 point for a temperature of 35.1–36.0°C or 39.0–
39.9°C, and 0 point for a temperature of 36.1–38.9°C; (ii)
hypotension: 2 points for an acute hypotensive event with
decreases in systolic and diastolic blood pressure of >30 and
>20 mmHg, respectively, use of intravenous vasopressor
agents, or systolic blood pressure <90 mmHg; (3) receipt of
mechanical ventilation: 2 points; (4) cardiac arrest: 4 points;
and (5) mental status: alert, 0; disoriented, 1 point; stuporous,
2 points; and comatose, 4 points [18]. Among laboratory tests,
azotaemia (serum blood urea nitrogen ≥7.14 mM and/or
serum creatinine ≥123.76 lM), C-reactive protein (CRP) and
WBC counts in blood were checked as risk factor variables;
CRP was stratiﬁed into four levels (<5.0, 5.0–9.99, 10.0–19.99
and ≥20.0 mg/dL), and WBC counts into three levels
(<10 000, 10 000–19 999 and ≥20 000 per mm3). In addition,
after reporting of the results of urine culture, antimicrobial
resistance of uropathogens and initial antibiotic use were
collected as risk factor variables. Treatment regimens in
hospitals were recorded. Initial antimicrobial therapy was
considered concordant if the treatment regimen included one
or more antibiotics found to be active against the causative
organism by in vitro susceptibility testing, and if the dose and
route of administration conformed to current medical stan-
dards [2].
Microbiological data
Urine and blood culture were processed at the time of
admission. Aetiological agents were determined when organ-
isms at ≥105 CFU/mL were identiﬁed on urine culture, and/or
urinary pathogens were isolated from blood culture [19,20].
Species identiﬁcation and susceptibilities to antimicrobial
agents were determined by means of a semi-automated
system (VITEK, bioMerieux, Hazelwood, MO, USA; or Micro-
scan, DADE Behring, West Sacramento, CA, USA).
Extended-spectrum b-lactamase-producing isolates were
deﬁned as Enterobacteriaceae proven to be positive by
extended-spectrum b-lactamase test in either the semi-auto-
mated system or a double disc diffusion test according to the
criteria of the CLSI [21].
Statistical methods
We compared participants’ medical and laboratory data using
chi-square tests or Fisher’s exact tests for categorical
variables, and independent t-tests or Mann–Whitney tests for
continuous variables. A backward stepwise multiple logistic
regression analysis was performed to evaluate the effect of
independent variables on early clinical failure. A p-value of
<0.05 (two-sided) was considered statistically signiﬁcant. SPSS
version 20.0 for Windows (SPSS Inc., Chicago, IL, USA) was
used for statistical analyses.
Results
Patient population and clinical characteristics
During the study period a total of 1138 women with a
diagnosis of CO-APN were screened. Of these, 76 women
were excluded because their ﬁnal clinical outcomes were not
available. Finally, 1062 women with a diagnosis of CO-APN
were enrolled (Fig. 1). The median age of the 1062 women
was 56.0 years (interquartile range, 39.0–71.0 years). Of these
patients, 784 (73.8%) gave positive urine and/or blood cultures.
Escherichia coli was the most common pathogen (708 patients;
90.3%) and non-E. coli bacteria were isolated from 76 patients
(9.7%). The latter comprised 23 Klebsiella pneumoniae, nine
Proteus mirabilis, six Enterococcus faecalis, ﬁve Enterococcus
faecium, four Pseudomonas aeruginosa, four Streptococcus spp.,
two Staphylococcus spp., two Providentia spp. and others. Of the
E. coli isolates tested, 78.7% were susceptible to ﬂuoroquino-
lone, 72.2% to trimethoprim-sulfamethoxazole, 90.7% to
cefotaxime and 99.7% to imipenem (Table 1).
After 72 h of treatment the patients were classiﬁed into
either the early clinical success group (840 cases; 79.1%) or the
early clinical failure group (222 cases; 20.9%) according to the
deﬁnitions above. Table 2 shows the demographic, clinical and
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laboratory characteristics of the patients according to their
early clinical response. The median age of the early clinical
failure group was higher than that of the early clinical success
group, and more of the former were postmenopausal. The
frequencies of diabetes mellitus, cerebrovascular disorders,
malignancy and chronic liver diseases were signiﬁcantly higher
in the early clinical failure group than in the early clinical
success group. In terms of clinical features, more patients in
the early failure group suffered from vomiting and had Pitt
scores ≥2. The proportions of patients with blood WBC
counts >20 000/mm3, CRP level >20 mg/dL and azotaemia
were also signiﬁcantly higher in the early clinical failure group
than in the early clinical success group
As initial treatment regimens, intravenous antimicrobial
agents were used in 1055 cases (99.3%) and oral antimicrobial
agents in seven cases (0.7%). More patients in the early clinical
failure group received third-generation cephalosporins and
fewer of them received second-generation cephalosporins or
aminoglycosides (Table 2).
Clinical implications of the early clinical failure in women with
CO-APN
Table 2 presents the overall clinical outcomes of the patients
in the two groups. Final clinical failure was more common in
the early clinical failure group than in the early clinical success
group (14.9% vs 2.3%; p <0.001) and deaths were also more
frequent: 6.8% (15/220) in the early clinical failure group and
0.1% (1/840) in the early clinical success group. Median times
(interquartile range) to defervescence were 5 (4–6) days and 2
(1–2) days (p <0.001), and median hospitalization durations
(interquartile range) were 9 (7–14) and 7 (5–9) days in the
early clinical failure and early clinical success group, respec-
tively (p <0.001) (Table 2).
Factors related to early clinical failure in women with
CO-APN
In order to identify the risk factors associated with early
clinical failure, multiple regression analysis was performed
TABLE 1. Antimicrobial susceptibilities of Enterobacteriaceae (Escherichia coli and non-E. coli) isolated from community-onset
acute pyelonephritis patients (n = 743), South Korea, 2010–2012
Antibiotics
E. coli (n = 708) Non-E. coli (n = 35)
Resistant (n) Susceptible (n) Total (n) Susceptibility (%) Resistant (n) Susceptible (n) Total (n) Susceptibility (%)
Amikacin 18 690 708 97.5 1 28 29 96.6
AMOX/CLA 111 453 564 80.3 11 19 30 63.3
Ampicillin 422 274 696 39.4 32 1 33 3.0
AMP/SUL 78 145 223 65.0 1 2 3 66.7
Cefazolin 89 300 389 77.1 4 6 10 60.0
Cefuroxime 15 196 211 92.9 2 3 5 60.0
Cetotaxime 65 635 700 90.7 4 28 32 87.5
Ceftriaxone 13 189 202 93.6 2 3 5 60.0
Ceftazidime 65 638 703 90.8 5 29 34 85.3
Cefepime 58 641 699 91.7 4 28 32 87.5
FQ 151 557 708 78.7 11 24 35 68.6
Gentamicin 159 545 704 77.4 7 26 33 78.8
Imipenem 2 703 705 99.7 0 34 34 100
Meropenem 4 575 579 99.3 0 23 23 100
Piperacillin 335 234 569 41.1 19 1 20 5.0
SXT 169 440 609 72.2 6 17 23 73.9
Tobramycin 152 525 677 77.5 7 18 25 72.0
TZP 28 633 661 95.8 3 17 20 85.0
AMOX/CLA, amoxicillin/clavulanate; AMP/SUL, ampicillin/sulbactam; FQ, ﬂuoroquinolone (ciproﬂoxacin or levoﬂoxacin); SXT, trimethoprim-sulfamethoxazole; TZP, piperacillin/
tazobactam.
1245 patients with community-acquired 
acute pyelonephritis (APN) 
107 patients  
Male or duplicated
1138 women with APN 
76 patients 
Lost to follow up or no 
information about clinical 
outcome 1062 patients with information about clinical 
outcome
Urine and/or blood culture 
negative in 278 patients 
840 patients showing 
early clinical success 
222 patients showing 
early clinical failure 
Urine and/or blood culture 
positive in 784 patients
Gram-positive or non-
enterobacterial Gram-
negative pathogens in 
41 patients 
743 culture-confirmed 
patients with enterobacterial 
pathogens.  
174 patients 
showing early 
clinical failure 
569 patients 
showing early 
clinical response 
FIG. 1. Consort ﬂow diagram.
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using the demographic, clinical and historical variables identi-
ﬁed by simple analysis. Table 3 shows the ﬁnal multiple logistic
regression models for the total patients with CO-APN
(n = 1062) and for the subgroup infected by Enterobacteria-
ceae (n = 743).
Factors identiﬁed based on the 1062 patients included
diabetes mellitus, chronic liver diseases, malignancy, Pitt score
≥2, WBC count ≥20 000/mm3 of blood, serum CRP level
≥20 mg/dL, azotaemia and history of antibiotic usage within
1 year (Table 3). These factors increased the risk of early
clinical failure from 1.5 to 3.3-fold.
To assess the effects of antibiotic resistance and empirical
antibiotic treatment, we analysed the factors associated with
early clinical failure in the 743 patients with Enterobacteriaceae
as urinary pathogens, and the antibiotic susceptibility of these
pathogens. This revealed that ﬂuoroquinolone resistance,
extended spectrum b-lactamase production by the uropatho-
gens and inadequacy of initial antibiotics were additional
variables inﬂuencing early clinical failure. We then performed a
multiple logistic regression analysis using all of these risk
factors (Table 3). This revealed that ﬂuoroquinolone resis-
tance was independently associated with the early clinical
failure of women with CO-APN due to Enterobacteriaceae, in
addition to the risk factors for early clinical failure already
identiﬁed in the total cohort of 1062 patients except
azotaemia.
Factors related to mortality in women with CO-APN
To compare the factors related to early clinical failure and
those related to mortality, we performed a logistic regression
TABLE 2. Demographic and clinical characteristics of study subjects by early clinical failure, South Korea, 2010–2012
Early clinical failure (n = 222) n (%) Early clinical success (n = 840) n (%) p valuea
Demographic data
Age (median, 1Q–3Q) (years) 60.5, 43.8–72.0 54.0, 38.0–71.0 0.023b
Elderly (≥65 years) 98 (44.1) 310 (36.9) 0.049
Past history
Admission within 1 year 65/202c (32.2) 168/787c (21.3) 0.001
Antibiotic use within 1 year 71/168c (42.3) 208/717c (29.0) <0.001
Previous urinary tract infection 63/181c (34.8) 216/767c (28.2) 0.078
Co-morbid conditions
Diabetes mellitus 84 (37.8) 207 (24.6) <0.001
Congestive heart failure 14 (6.3) 50 (6.0) 0.844
Cerebrovascular disorders 30 (13.5) 59 (7.0) 0.002
Malignancy 16 (7.2) 28 (3.3) 0.01
Chronic liver diseases 16 (7.2) 20 (2.4) <0.001
Chronic renal diseases 18 (8.1) 41 (4.9) 0.062
Dementia 10 (4.5) 20 (2.4) 0.089
Menopause 145 (65.3) 451 (53.7) 0.002
Urinary tract conditions
History of catheterization within 1 month 5 (2.3) 11 (1.3) 0.305
Neurogenic bladder 3 (1.4) 10 (1.2) 0.741
Urolithiasis 6 (2.7) 11 (1.3) 0.141
Clinical features
Pitt scored 1 42 (18.9) 169 (20.1) 0.69
Pitt score 2–4 53 (23.9) 84 (10.0) <0.001
Lower urinary tract infection symptomse 139 (62.6) 577 (68.7) 0.086
Flank pain 77 (34.7) 308 (36.7) 0.585
Costovertebral angle tenderness 153 (68.9) 577 (68.7) 0.948
Vomiting or nausea 85 (38.3) 217 (25.8) <0.001
Laboratory features
Pyuria (≥5~9 leucocytes/high-power ﬁeld) 206 (92.8) 746 (88.8) 0.083
Haematuria (≥5~9 red blood cells/high-power ﬁeld) 138 (62.2) 433 (51.5) 0.005
White blood cells ≥20 000/mm3 of blood 45 (20.3) 58 (6.9) <0.001
C-reactive protein ≥20 mg/dL 98 (44.1) 223 (26.5) <0.001
Azotaemiaf 63 (28.4) 105 (12.5) <0.001
Initial antibiotics regimens
Second-generation cephalosporins 10 (4.5) 177 (21.1) <0.001
Third-generation cephalosporins 118 (53.2) 364 (43.3) 0.009
Fluoroquinolones 53 (23.9) 178 (21.2) 0.389
Aminoglycosides 2 (0.9) 75 (8.9) <0.001
Other antibiotics 39 (17.6) 46 (5.5) <0.001
Clinical outcomes
Final clinical failure 33 (14.9) 19 (2.3) <0.001
Mortality 15 (6.8) 1 (0.1) <0.001
Time to fever clearance (days), median (1Q–3Q) 5 (4–6) 2 (1–2) <0.001b
Hospitalization period (days), median (1Q–3Q) 9 (7–14) 7 (5–9) <0.001b
Microbiological failure 11/78c (14.1) 43/471c (9.1) 0.172
aChi-square test or Fisher’s exact test.
bMann–Whitney test.
cDenominators were the number of patients whose data were available in each group.
dThe Pitt bacteraemia score was calculated using the following criteria [18]: (i) oral temperature: 2 points for a temperature of ≤35°C or ≥40°C, 1 point for a temperature of 35.1–
36.0°C or 39.0–39.9°C, and 0 point for a temperature of 36.1–38.9°C; (ii) hypotension: 2 points for an acute hypotensive event with decreases in systolic and diastolic blood
pressure of >30 and >20 mmHg, respectively, use of intravenous vasopressor agents, or systolic blood pressure <90 mmHg; (iii) receipt of mechanical ventilation: 2 points; (iv)
cardiac arrest: 4 points; and (v) mental status: alert, 0 point; disoriented, 1 point; stuporous, 2 points; and comatose, 4 points.
eLower urinary tract infection symptoms contain dysuria, frequency, urgency and nocturia.
fAzotaemia was deﬁned as serum blood urea nitrogen ≥7.14 mM and/or serum creatinine ≥123.76 lM.
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analysis for mortality in all 1062 patients (Table 4). The 16
patients who died as a result of this episode of infection were
compared with the 1046 surviving patients. Pitt score ≥2
emerged as a risk factor common to mortality and early clinical
failure, and age >65 years, urolithiasis and haematuria were
signiﬁcant risk factors for mortality only. Pitt score ≥2 and
haematuria increased the risk of death 18-fold and 11-fold,
respectively, and age >65 years and urolithiasis increased the
risk of death 11-fold and 13-fold, respectively. Neither
underlying chronic liver disease, malignancy and diabetes
mellitus nor a history of previous antibiotic usage contributed
to mortality.
Discussion
In clinical practice, physicians need to consider complicating
factors such as urinary tract abnormalities and underlying
diseases when making decisions about treatment of patients
with CO-APN [19–21]. Patients who have risk factors for
mortality or poor clinical response [9,10,22] must be hospi-
talized. Patients who are at risk of clinical failure after 72 h of
treatment also need hospitalization because decisions to
modify treatment or carry out further work up might be
required at short notice. Furthermore, this study showed that
early clinical failure was associated with failure to improve
subsequently, and even with death.
Interestingly, we found that the variables predictive of early
clinical failure fell into three categories: the ﬁrst were
underlying diseases such as chronic liver disease, malignancy
and diabetes; the second consisted of parameters reﬂecting
the severity of infection such as Pitt score, azotaemia, serum
CRP level and WBC counts in the blood, while the third
category consisted of history of antibiotic usage within 1 year
among the 1062 cases, and ﬂuoroquinolone resistance in the
subgroup of patients with enterobacterial infections. It is
reasonable to expect that these three categories of variable
would inﬂuence treatment outcome.
Risk factors for mortality due to CO-APN were age
>65 years, septic shock, bedridden status and immunosup-
pression in one report [9], and age, McCabe score II–III, Pitt
score ≥2 and hospital-acquired APN in another report [22]. In
this study, age >65 years, Pitt score ≥2, haematuria and
urolithiasis were associated with mortality. Interestingly,
underlying diseases, such as chronic liver disease, malignancy,
diabetes and antibiotic resistance, did not contribute to
mortality, whereas age and severity of infection did. Antibiotic
resistance was also not associated with mortality in previous
reports [9,22].
Community-onset APN is a common infection caused mostly
by E. coli. Although antibiotic resistance of uropathogens varied
according to regions or countries, the epidemiology and clinical
characteristics of the disease are globally similar. Comparing the
populations of several studies, two studies were similar to ours
[9,22] but one was different; the patients’ average age was
younger and co-morbidities were fewer [10]. In that report,
need for hospitalization, antibiotic-resistant infecting organisms,
diabetes mellitus and renal stones were risk factors for ﬁnal
TABLE 4. Related factors for mortality of community-onset acute pyelonephritis in ﬁnal model of multiple logistic regression
(n = 1062), 2010–2012
Characteristics Survivors (n) Deaths (n)
Rate of
mortality (%)
Simple Multiple
OR (95% CI) p value OR (95% CI) p value
Total patients 1046 16 1.5
Age group (years)
Elderly (≥65) 393 15 3.7 24.924 (3.28–189.41) 0.002 10.649 (1.26–90.05) 0.03
Pitt score 1 211 0 0
Pitt score 2–4 124 13 9.5 24.847 (6.979–88.457) <0.001 17.984 (4.35–74.39) <0.001
Laboratory features
WBC ≥20 000/mm3 of blood 97 6 5.8 5.870 (2.088–16.500) 0.001
Azotaemia 158 10 6.0 9.367 (3.357–26.138) <0.001 2.947 (0.92–9.445) 0.069
C-reactive protein ≥20 mg/dL 316 5 1.6 1.050 (0.362–3.047) 0.928
Haematuria 556 15 2.6 13.219 (1.74–100.441) 0.013 11.095 (1.37–89.94) 0.024
Underlying medical conditions
Diabetes mellitus 285 6 2.1 1.602 (0.577–4.448) 0.366
Congestive heart failure 60 4 6.3 5.478 (1.715–17.495) 0.004
Cerebrovascular disorders 84 5 5.6 5.206 (1.767–15.335) 0.003
Chronic liver diseases 36 0 0 >0.999
Chronic renal diseases 58 1 1.7 1.136 (0.147–8.747) 0.903
Malignancy 42 2 4.5 3.415 (0.752–15.511) 0.112
Dementia 27 3 10.0 8.709 (2.345–32.352) 0.001
Urinary tract conditions
Urolithiasis 15 2 11.8 9.819 (2.049–47.047) 0.004 13.171 (1.9–91.55) 0.009
Past history
Admission within 1 year 225 8 3.4 4.444 (1.526–12.943) 0.006
Antibiotic use within 1 year 274 5 1.8 1.562 (0.491–4.964) 0.45
Full model : Elderly, Pitt score, white blood cells ≥20 000 per mm3 of blood, azotaemia, haematuria, congestive heart failure, cerebrovascular disorders, dementia, urolithiasis and
history of admission.
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clinical failure [10]. Despite the difference in populations, that
study and ours shared several factors such as diabetes, renal
stones and antibiotic-resistant infecting organisms either as
predisposing factors for ﬁnal clinical failure, early clinical failure
or mortality. Furthermore, we provided the initial medical
presentations of CO-APN patients requiring hospitalization.
Empirical antibiotic usage and antibiotic susceptibility can also
inﬂuence treatment results. Because the guidelines for antibi-
otic usage in CO-APN in South Korea are similar to those in
other countries and our risk factors for poor clinical response
at 72 h were composed of the ﬁndings at the initial presenta-
tion, we consider that the results of our study are applicable in
other regions.
In the light of all these ﬁndings, we would like to
recommend that CO-APN patients with the following medical
presentation should be observed closely: (i) patients with age
≥65 and co-morbidities of chronic liver disease, diabetes,
malignancy and renal stones; (ii) patients with a Pitt score ≥2,
azotaemia, haematuria, WBC count ≥20 000/mm3 and CRP
level ≥20 mg/dL; (iii) patients with a history of antibiotic usage
within the previous year.
The signiﬁcance of this study is that it is a prospectively
performed multicentre study of a large number of cases aiming
to identify simple clinical factors predicting an early clinical
response in patients with CO-APN to help physicians decide on
the need for patient admission. However, this study also has
several potential limitations. First, it was not possible to assess
microbial factors or host genetic factors that might inﬂuence
individual susceptibility to urinary tract infections and clinical
course. Second, as this was a prospective, observational study
without any interventions in terms of diagnostic approach and
therapeutic regimen, the procedures used to diagnose structural
and functional abnormalities of the urinary tract were not
performed in all patients. Third, the frequencies of co-morbid-
ities and antibiotic usage may be underestimated because the
information was obtained from hospital medical records and
questionnaires completed by patients and their families.
In conclusion, careful review of underlying medical condi-
tions and antibiotic usage history, a thorough physical exam-
ination and initial laboratory test would help physicians to
identify patients requiring close observation and to make
appropriate decisions at initial presentation in patients with
CO-APN.
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